September 21, 2015.
The U.S. Department of Health and Human Services Secretary (HHS) has announced new steps to increase access to treatments for opioid dependence and prevention of opioid overdose. Among the planned changes, reports BioDelivery Sciences International (Raleigh, NC), is a move to expand access to medication assisted treatment (MAT) by revising the regulations that limit the prescribing of buprenorphine to treat opioid dependence.
HHS reports that 2.5 million people in the U.S. currently need treatment for opioid dependence; however, fewer than 1 million are receiving it. Under current regulations, physicians certified can prescribe buprenorphine treatment for opioid dependence for up to 30 patients initially and then after one year can request authorization to prescribe up to a maximum of 100 patients. As a result, access to care is limited and physicians are often forced to turn away patients seeking care.
Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences said that the move "is a major step forward in providing access to treatment for patients and their families who are dealing with opioid addiction".
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.